Skip to main content
Contact Us
Subscribe
E-Edition
81°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Lexicon Pharmaceuticals, Inc.
Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)
June 23, 2025
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
LXRX
Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)
June 18, 2025
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
LXRX
SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology
May 19, 2025
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
LXRX
Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)
February 18, 2025
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
LXRX
Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain
January 21, 2025
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
LXRX
Lexicon Appoints Scott Coiante as Chief Financial Officer
January 02, 2025
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
LXRX
Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)
December 20, 2024
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
LXRX
Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
November 26, 2024
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
LXRX
Lexicon Pharmaceuticals to Participate in December Investor Conferences
November 25, 2024
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
LXRX
Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA
November 22, 2024
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
LXRX
Lexicon Appoints Ivan H. Cheung to Board of Directors
November 20, 2024
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
LXRX
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.